Breast Cancer Clinical Trial

Soy Isoflavones Supplementation in Treating Women at High Risk For or With Breast Cancer

Summary

RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming. The use of soy isoflavones supplements may prevent or treat early stage breast cancer. PURPOSE: This clinical trial studies soy isoflavones supplementation in treating women at high risk for or with breast cancer.

View Full Description

Full Description

PRIMARY OBJECTIVES: I. To assess whether magnetic resonance imaging (MRI) volume (equivalent to 3-dimensional mammographic density) is reduced in high-risk women or those with invasive breast cancer or DCIS who are supplemented daily with soy (5p mg total isoflavones as aglycone) compared to placebo (microcrystalline cellulose) tablets for 1 year.II. To assess whether cell proliferation and apoptosis, as measured by Ki67 and caspase 3 staining, respectively, of breast epithelial cells is altered with soy treatment.SECONDARY OBJECTIVES: I. To assess whether other intermediate molecular markers including estrogen receptor alpha (ER alpha) and ER beta differ between women supplemented with soy vs placebo. OUTLINE: Patients are randomized to 1 of 2 treatment arms.ARM I: Patients receive oral soy isoflavones supplement once daily for12 months in the absence of disease progression.ARM II: Patients receive oral placebo once daily for 12 months in the absence of disease progression.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Women at high risk for breast cancer, defined as any of the following groups:
Five year Gail risk > 1.7%
Known BRCA1/BRCA2 mutation carrier
Family history consistent with hereditary breast cancer
Prior biopsy exhibiting atypical hyperplasia or lobular carcinoma in situ (LCIS)
History of invasive breast cancer or ductal carcinoma in situ (DCIS) and have completed standard therapy including tamoxifen/aromatase inhibitor or will not be treated with tamoxifen/aromatase inhibitor
Signed Informed Consent

Exclusion Criteria:

Metastatic breast cancer
Undergoing treatment (chemotherapy, radiation, or SERMs)
Pregnancy or breast-feeding, or planning to become pregnant within one year prior to study entry
Regular soy consumers (i.e., < once per week of soy food, soy supplements or other products)
Known food allergies such as to soy or nuts
Not willing to avoid soy foods/supplements during study period
Current users of exogenous hormones or oral contraceptive or planning to use exogenous hormones during the duration of the study
Cannot stop taking aspirin or NSAIDs within a week of breast biopsy
Active participant in other ongoing trials

Study is for people with:

Breast Cancer

Estimated Enrollment:

110

Study ID:

NCT01219075

Recruitment Status:

Active, not recruiting

Sponsor:

University of Southern California

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

University of Southern California
Los Angeles California, 90033, United States

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Estimated Enrollment:

110

Study ID:

NCT01219075

Recruitment Status:

Active, not recruiting

Sponsor:


University of Southern California

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider